David N. Wald

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML”.

Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML

UNC Libraries(2020)10.17615/zvb0-bn49

N/A

0DataRank · unranked

0 citations

Mukesh K. Agarwal, Munna L. Agarwal, Bryan L. Roth, Amitabha Chakrabarti, David N. Wald +4 more

Identification of 6-Benzylthioinosine as a Myeloid Leukemia Differentiation-Inducing Compound

UNC Libraries(2020)10.17615/2mn6-3206

N/A

0DataRank · unranked

0 citations

William Tse, Zizhen Kang, Munna L. Agarwal, Bryan L. Roth, David N. Wald +6 more

Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-03117-w

N/A

0DataRank · unranked

7 citations

Sheela Karunanithi, Bruce A. Posner, Hanspeter Niederstrasser, Hong Cheng, Yuriy Federov +6 more

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1586

N/A

0DataRank · unranked

88 citations

Changjin Hong, Robert Schauner, Boro Dropulić, Paolo F. Caimi, Marcos de Lima +6 more

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition

Frontiers in Oncology(2022)10.3389/fonc.2022.824594

N/A

0DataRank · unranked

7 citations

Jayadev Joshi, I‐Ju Yeh, Yong‐Qiu Doughman, Daniel Blankenberg, David N. Wald +2 more

Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.09.05.506592

N/A

0DataRank · unranked

0 citations

Benjamin G. Luttge, Curtis Dobrowolski, David N. Wald, Deborah K. McMahon, Ghady Haidar +6 more

NK cells from COVID-19 positive patients exhibit enhanced cytotoxic activity upon NKG2A and KIR2DL1 blockade

Frontiers in Immunology(2023)10.3389/fimmu.2023.1022890

N/A

0DataRank · unranked

17 citations

Robert Schauner, Juanita Burke, Jade Borocz, Smitha Vasana, Lukasz Sobieraj +7 more

Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps273

N/A

0DataRank · unranked

3 citations

David L. Bajor, Amr Mohamed, Sakti Chakrabarti, Jane Reese, Hillard M. Lazarus +4 more

Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies

Cytometry Part B Clinical Cytometry(2024)10.1002/cyto.b.22158

N/A

0DataRank · unranked

4 citations

Basem M. William, Brenda Cooper, Masumi Ueda Oshima, Folashade Otegbeye, Marcos J. de Lima +6 more

Single cell and bulk RNA expression analyses identify enhanced hexosamine biosynthetic pathway and O-GlcNAcylation in acute myeloid leukemia blasts and stem cells

Frontiers in Immunology(2024)10.3389/fimmu.2024.1327405

N/A

0DataRank · unranked

5 citations

Jordan D. Cress, Changjin Hong, David N. Wald, Parameswaran Ramakrishnan, Robert Schauner

In vivo tracking of CAR-T cells in tumors via nanobubble-based contrast enhanced ultrasound

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.06.651695

N/A

0DataRank · unranked

2 citations

Jude Franklin, Reshani Perera, Zachary Jackson, Hosahalli Vasanna, Michael C. Kolios +3 more